Western tradition · Flavonoid

Apigenin 芹菜素

A flavone from parsley and chamomile that inhibits CD38 (NADase) — preserving NAD+ through a complementary mechanism to NMN or NR.

↑ iHerb link is an affiliate link — we may earn a commission at no cost to you.

Origin & tradition

Not traditional as an isolate, though apigenin is abundant in chamomile tea and parsley, both used medicinally for centuries.

Why longevity buyers care

Key active: Apigenin (flavone — CD38 inhibitor & SIRT1 modulator).

Apigenin inhibits CD38, an ectoenzyme that consumes ~60% of cellular NAD+. This creates mechanistic synergy with NMN/NR: more precursor + less degradation. Apigenin also modulates SIRT1, CK2, and NF-κB. Most longevity evidence is preclinical; anti-cancer and anti-inflammatory human trials are ongoing.

Effect summary

Studied health outcomes

Editorial summary — This table is curated by hand from published research consensus, not automatically calculated from our trial database. Grades reflect our interpretation of the literature. Treat as a starting point, not a definitive verdict. See the Evidence panel below for the underlying trial and paper counts sourced directly from ClinicalTrials.gov and PubMed.
Health outcomeEffectMagnitudeGrade
CD38 inhibition / NAD+ preservationMechanism well-characterized; human outcome data limitedIncreasesMinorC
Anxiety / sleep (chamomile)DecreasesMinorC
Inflammation markersDecreasesMinorC

Grade: A = robust RCTs · B = several RCTs / meta-analysis · C = limited or mixed RCTs · D = observational or early data

Dosage guidance

How Apigenin is typically used

Typical dose
50–200 mg/day
Form
capsule
Timing
any time, with meals for better absorption

Apigenin inhibits CD38, an enzyme that consumes NAD+. Chamomile tea is a rich dietary source (~3–5mg per cup). Used by some longevity practitioners to complement NMN/NR by reducing NAD+ degradation. Human trial data is limited.

Informational only — not a prescription or personalised medical advice. Consult a qualified clinician before starting any supplement or medication.

Evidence summary

What the research actually says

70Evidence confidence
Human RCT evidence15 randomized controlled trials · 34 meta-analyses / systematic reviews

Strong preclinical (CD38/NAD+/SIRT1); human cancer/anti-inflammatory trials

Apigenin inhibits CD38, an ectoenzyme that consumes ~60% of cellular NAD+. This creates mechanistic synergy with NMN/NR: more precursor + less degradation. Apigenin also modulates SIRT1, CK2, and NF-κB. Most longevity evidence is preclinical; anti-cancer and anti-inflammatory human trials are ongoing.

17registered clinical trials reference this intervention
    0selected peer-reviewed papers (longevity / aging angle)
      Key active: Apigenin (flavone — CD38 inhibitor & SIRT1 modulator) — a multi-compound botanical extract, so activity is not reducible to a single molecule.

      According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed. Counts auto-refresh weekly; last checked 2026-06-12. They include trials across many endpoints, not only longevity.

      Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.

      Compare the evidence

      Related ingredients

      Suppliers

      No Apigenin suppliers listed yet

      Tell us what you need and we will source suppliers for you.

      Request sourcing help